Surgery in Non–Small-Cell Lung Cancer

Article

Surgical management of the patient with non–small-cell lung cancer (NSCLC) is complex. When should stereotactic body radiation therapy be used? What are the advantages of video-assisted thoracic surgery? Test your knowledge in our latest quiz.

Surgical management of the patient with non–small-cell lung cancer (NSCLC) is complex. When should stereotactic body radiation therapy be used? What are the advantages of video-assisted thoracic surgery? Test your knowledge in our latest quiz.

Question 1

Answer and Question 2 on Next Page »

Answer

B.

Surgery in patients with one N2 lymph node station involved by a lymph node smaller than 3 cm.

This practice pattern was selected by 90.5% of the member institutions, according to the NCCN. In addition, 80% said they would use endobronchial ultrasound with or without endoscopic ultrasound in initial evaluation of the mediastinum, and 40.5% noted they would use pathologic evaluation of the mediastinum, after neoadjuvant therapy, to make a final decision before surgery.

Question 2

Answer and Question 3 on Next Page »

Answer

C.

5 cm

The guidelines note that such patients should be counseled about the subsequent risk of locoregional and distant failure.

Question 3

Answer and Question 4 on Next Page »

Answer

C.

Race

The study found that half of patients alive at 5 years were alive at 10 years, with 10-year survival “associated with younger age, earlier stage, non-squamous histology, lobectomy, and fewer comorbidities, but not race.”

Question 4

Answer and Question 5 on Next Page »

Answer

B.

True

The study compared overall survival and lung cancer–specific survival among patients after lobectomy, segmentectomy, or wedge resection.

Question 5

Answer on Next Page »

Answer

D.

All of the above

VATS is also associated with a shorter length of hospitalization, minimal locoregional recurrence, and improved discharge independence in older and high-risk patients, according to the guidelines.

Recent Videos
4 KOLs are featured in this series.
4 KOLs are featured in this series.
4 KOLs are featured in this series.
It may be crucial to test every patient for markers such as BRAF V600E mutations, NRG1 fusions, and KRAS G12C mutations to help manage pancreatic cancers.
4 KOLs are featured in this series.
Tanios S. Bekaii-Saab, MD, emphasizes the idea of moving targeted therapies to earlier lines of treatment to further improve outcomes in pancreatic cancer.